This is a prospective, randomized, open-label, multicenter Phase 3 study evaluating the efficacy and safety of 177Lu-PSMA-I&T versus a switch in standard of care hormone therapy in men with metastatic
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
GenesisCare May Grand Rounds
Update on GenesisCare’s radiopharmaceutical care and research
On May 18th, GenesisCare will be hosting a Global Grand Rounds session on our global theranostics research program, which will include an overview of key active studies in the United States and Australia.